Why the study?
Does the choice between third-generation and second-generation oral contraceptives impact the risk of mortality from myocardial infarction and deep vein thrombosis in women?
Does the choice between third-generation and second-generation oral contraceptives impact the risk of mortality from myocardial infarction and deep vein thrombosis in women?
Answers are grounded in this paper and cite their sources.
The overall cardiovascular mortality risk does not appear significantly different between second- and third-generation oral contraceptives, as potential reductions in MI deaths with third-generation agents are offset by an increase in DVT-related deaths.
OBJECTIVES: To summarise the epidemiological evidence on the relationship between second- (OC2) and third-generation (OC3) oral contraceptives (OC) and the mortality associated with deep vein thrombosis (DVT) and myocardial infarction (MI), and to extrapolate and balance the evidence for these risks to the population of French OC users. METHODS: All studies published on the risk of MI during OC2 and OC3 use were analysed. For DVT the Committee for Proprietary Medicinal Products public assessment report published in 2001 and more recent studies published on this topic were used. The estimates of odds ratios (OR) for risk of death from DVT or MI were extracted from the published manuscripts. ORs were used to calculate the aetiological fraction of risk for death from DVT and MI in the population; the relative impact of OC3 compared to OC2 use was expressed as an excess risk of death overall and by age group for French women. RESULTS: Compared with OC2, the use of OC3 would prevent a maximum of 24 deaths from MI per year and induce a maximum of 16 deaths. Conversely, OC3 would induce 282-940 excess cases of DVT per year, resulting in 28-94 pulmonary embolisms and 3-19 deaths in the 4.7 million French OC users. CONCLUSION: Balancing the evidence, it is difficult to conclude that the overall cardiovascular risk is significantly lower for either of the two OC schemes.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2005) conducted a review in Oral contraceptive use (n=4,700,000). Third-generation oral contraceptives (OC3) vs. Second-generation oral contraceptives (OC2) was evaluated on Mortality associated with deep vein thrombosis (DVT) and myocardial infarction (MI).
Synapse has enriched 10 related papers. Consider them for comparative context: